Patents Assigned to NeoRx Corporation
  • Patent number: 7115720
    Abstract: The invention provides a complex comprising a) a compound formula I: wherein R1, X and n have any of the values described in the specification, or a pharmaceutically acceptable salt thereof; and b) a radionuclide. The complexes are useful as diagnostic agents and as therapeutic agents. The invention also provides methods and intermediates useful for preparing the complexes of the invention, as well as therapeutic and diagnostic methods.
    Type: Grant
    Filed: July 8, 2003
    Date of Patent: October 3, 2006
    Assignee: Neorx Corporation
    Inventor: Alan R. Fritzberg
  • Patent number: 7115248
    Abstract: Radiolabeled annexin and modified annexin conjugates useful for imaging vascular thrombi are described. Methods for making and using such radiolabeled annexin conjugates are also provided.
    Type: Grant
    Filed: April 8, 2004
    Date of Patent: October 3, 2006
    Assignee: NeoRx Corporation
    Inventors: Sudhakar Kasina, John M Reno, Louis J Theodore
  • Patent number: 7097823
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Grant
    Filed: February 23, 2004
    Date of Patent: August 29, 2006
    Assignee: NEORX Corporation
    Inventors: Alan R. Fritzberg, Paul G. Abrams, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John
  • Patent number: 7094885
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Grant
    Filed: June 20, 2003
    Date of Patent: August 22, 2006
    Assignee: NeoRx Corporation
    Inventor: Alan R. Fritzberg
  • Patent number: 7094550
    Abstract: A method for treating or preventing cardiovascular pathologies by administering a compound of the formula (I): wherein Z is C?O or a covalent bond; Y is H or O(C1–C4)alkyl, R1 and R2 are individually (C1–C4)alkyl or together with N are a saturated heterocyclic group, R3 is ethyl or chloroethyl, R4 is H or together with R3 is —CH2—CH2— or —S—, R5 is I, O(C1–C4)alkyl or H, and R6 is I, O(C1–C4)alkyl or H with the proviso that when R4, R5, and R6 are H, R3 is not ethyl; or a pharmaceutically acceptable salt thereof, effective to activate or stimulate production of TGF-beta to treat and/or prevent conditions such as atherosclerosis, thrombosis, myocardial infarction, and stroke is provided. Useful compounds include idoxifene and salts thereof. Further provided is a method for identifying a compound that is a TGF-beta activator or production stimulator is provided. Another embodiment of the invention is an assay or kit to determine TGF-beta in vitro.
    Type: Grant
    Filed: March 26, 2002
    Date of Patent: August 22, 2006
    Assignee: NeoRx Corporation
    Inventors: David J. Grainger, Paul R. Kemp
  • Patent number: 7084171
    Abstract: The invention provides a method of treating a mammal having, or at risk of, an indication associated with a TGF-beta deficiency comprising administering one or more agents that is effective to elevate the level of TGF-beta. The invention also provides novel compounds that elevate TGF-beta levels, as well as pharmaceutical compositions comprising compounds that elevate TGF-beta levels, and methods for detecting diseases associated with endothelial cell activation.
    Type: Grant
    Filed: April 19, 2004
    Date of Patent: August 1, 2006
    Assignee: NeoRx Corporation
    Inventors: David J. Grainger, James C. Metcalfe, Sudhakar Kasina
  • Patent number: 7070759
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Grant
    Filed: January 24, 2005
    Date of Patent: July 4, 2006
    Assignee: NeoRx Corporation
    Inventors: Alan R. Fritzberg, Paul G. Abrams, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John
  • Patent number: 6936700
    Abstract: The present invention provides for substituted metal chelating compounds in which at least two of the chelating atoms are nitrogen which are directly attached to aromatic rings and one or more of those nitrogen atoms has attached thereto a substituent other than hydrogen, and methods for making and using these compounds.
    Type: Grant
    Filed: January 17, 2003
    Date of Patent: August 30, 2005
    Assignee: NeoRx Corporation
    Inventor: Sudhakar Kasina
  • Publication number: 20050100545
    Abstract: Humanized antibodies which bind the NR-LU-13 antigen, conjugates containing such antibodies, and their use in pretargeting methods and conventional antibody therapy and immunodiagnosis are provided.
    Type: Application
    Filed: July 31, 2003
    Publication date: May 12, 2005
    Applicant: NeoRx Corporation
    Inventors: Scott Graves, John Reno, Robert Mallett, Mark Hylarides
  • Publication number: 20050036948
    Abstract: Radiolabeled annexin and modified annexin conjugates useful for imaging vascular thrombi are described. Methods for making and using such radiolabeled annexin conjugates are also provided.
    Type: Application
    Filed: April 8, 2004
    Publication date: February 17, 2005
    Applicant: NeoRx Corporation
    Inventors: Sudhakar Kasina, John Reno, Louis Theodore
  • Publication number: 20050008635
    Abstract: Humanized antibodies which bind the NR-LU-13 antigen, conjugates containing such antibodies, and their use in pretargeting methods and conventional antibody therapy and immunodiagnosis are provided.
    Type: Application
    Filed: February 25, 2004
    Publication date: January 13, 2005
    Applicant: NeoRx Corporation
    Inventors: Scott Graves, John Reno, Robert Mallett, Mark Hylarides, Stephen Searle, Andrew Henry, Jan Pedersen, Anthony Rees
  • Publication number: 20040241172
    Abstract: Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.
    Type: Application
    Filed: February 10, 2004
    Publication date: December 2, 2004
    Applicant: NeoRx Corporation
    Inventors: Donald B. Axworthy, Louis J. Theodore, Linda M. Gustavson, John M. Reno, Robert W. Mallett, Mark D. Hylarides, Alan R. Fritzberg
  • Patent number: 6767531
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: July 27, 2004
    Assignee: NeoRx Corporation
    Inventors: Alan R. Fritzberg, Paul G. Abrams, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John
  • Patent number: 6734208
    Abstract: The invention provides a method of treating a mammal having, or at risk of, an indication associated with a TGF-beta deficiency comprising administering one or more agents that is effective to elevate the level of TGF-beta. The invention also provides novel compounds that elevate TGF-beta levels, as well as pharmaceutical compositions comprising compounds that elevate TGF-beta levels, and methods for detecting diseases associated with endothelial cell activation.
    Type: Grant
    Filed: June 13, 2002
    Date of Patent: May 11, 2004
    Assignee: NeoRx Corporation
    Inventors: David J. Grainger, James C. Metcalfe, Sudhakar Kasina
  • Patent number: 6709652
    Abstract: Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.
    Type: Grant
    Filed: August 1, 2001
    Date of Patent: March 23, 2004
    Assignee: NeoRx Corporation
    Inventors: John M. Reno, Louis J. Theodore, Linda M. Gustavson
  • Patent number: 6663881
    Abstract: Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: December 16, 2003
    Assignee: NeoRx Corporation
    Inventors: Lawrence L. Kunz, John M. Reno
  • Publication number: 20030220233
    Abstract: Radiolabeled annexin and modified annexin conjugates useful for imaging vascular thrombi are described. Methods for making and using such radiolabeled annexin conjugates are also provided.
    Type: Application
    Filed: June 6, 2003
    Publication date: November 27, 2003
    Applicant: NeoRx Corporation
    Inventors: Sudhakar Kasina, John M. Reno, Louis J. Theodore
  • Publication number: 20030203958
    Abstract: Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.
    Type: Application
    Filed: December 27, 2002
    Publication date: October 30, 2003
    Applicant: NeoRx Corporation
    Inventors: Lawrence L. Kunz, Richard A. Klein, John M. Reno
  • Publication number: 20030158393
    Abstract: The present invention provides for substituted metal chelating compounds in which at least two of the chelating atoms are nitrogen which are directly attached to aromatic rings and one or more of those nitrogen atoms has attached thereto a substituent other than hydrogen, and methods for making and using these compounds.
    Type: Application
    Filed: January 17, 2003
    Publication date: August 21, 2003
    Applicant: NeoRx Corporation
    Inventor: Sudhakar Kasina
  • Publication number: 20030143233
    Abstract: The present invention provides vectors for expressing genomic streptavidin fusion cassettes. In the various embodiments, fusion proteins produced from these vectors are provided. In particular embodiments, fusion proteins comprising a single chain antibody and genomic streptavidin are provided as are vectors encoding the same. Also provided, are methods of using the fusion proteins of the present invention, in the absence and presence of a radiation-sensitizing agent, and in particular, the use of scFvSA fusion proteins as diagnostic markers or as a cell specific targeting agents.
    Type: Application
    Filed: September 16, 2002
    Publication date: July 31, 2003
    Applicant: NeoRx Corporation
    Inventors: Stephen Charles Goshorn, Scott Stoll Graves, Joanne Elaine Schultz, Yukang Lin, James Allen Sanderson, John M. Reno, Erica A. Dearstyne